Ocular Therapeutix, Inc.

We’re excited to share that enrollment for SOL-R, our second registrational trial in wet age-related macular degeneration (AMD), is closing this week. This represents a major milestone made possible by the outstanding work of our team and the incredible partnership with investigators, coordinators, and patients. This progress brings us one step closer to introducing a potential new treatment in retinal disease. Thank you to everyone who has helped us on our mission to redefine the retina experience. Learn more: https://ow.ly/H6ya50VZXW9 #RetinaRedefined #WetAMD

At ASRS – American Society of Retina Specialists 2025, our team shared updates from the HELIOS trial in diabetic retinopathy, reinforcing our mission to redefine the retina experience. Thank you to everyone who stopped by our booth and connected with our team. We’re excited for what’s ahead. Learn more about Ocular's mission at ocutx.com. #ASRS2025 #RetinaRedefined

This August, it’s all about the eyes. National Eye Exam Month is a reminder to prioritize regular eye exams, which may catch conditions like retinal disease early. Retinal disease can often develop without noticeable symptoms until vision loss occurs, making early detection critical. This month, make the time to protect your vision. #NationalEyeExamMonth #WetAMD #RetinaRedefined

We’re looking forward to hosting an Investor Day on September 30 in New York City. Hear updates from senior leadership and key opinion leaders on our corporate strategy, our mission to redefine the retina experience, and more. Learn more: https://ow.ly/4gh850WAhhm #RetinaRedefined

We’ve announced our second quarter 2025 financial results. The report highlights continued progress and our commitment to redefining the retina experience. Learn more: https://ow.ly/JgFe50WzXBe #RetinaRedefined

We’re looking forward to attending the 2025 Women in Ophthalmology Summer Symposium to reflect on the continued contributions and collaboration within the ophthalmology community. Our team is excited to support the inspiring leadership and mentorship driving the field forward. #WIO2025 #WomenInOphthalmology #RetinaRedefined

We’re excited to share that Ocular’s own Peter Kaiser, MD, Jeff Heier, MD, and Nadia Waheed, MD, MPH, have co-authored an article for Modern Retina, exploring how innovative clinical trial design is redefining the retina experience for patients with retinal disease, such as wet age-related macular degeneration (AMD). This piece spotlights our SOL trials in wet AMD, providing a closer look at how we’re designing studies that not only meet FDA guidance, but also reflect real-world clinical practice.  Read the full article here: https://bit.ly/45aUtgy #RetinaRedefined

Today, we celebrate the impactful contributions of our interns and co-ops!   At Ocular, we’re committed to empowering the next generation of leaders. Our interns and co-ops bring fresh perspectives, bold ideas, and a passion for impact. It's been inspiring to see them contribute meaningfully to our mission to redefine the retina experience.   Thank you to our 2025 cohort for your curiosity, dedication, and drive! #NationalInternDay #RetinaRedefined 2025 Interns and Co-Ops: Sebastian Dasilva, Alex Hao, Mia Guralnick, Andy Jung, Jackson Li, AADHIRA NAIR, Maggie Ondrey, Khadija Raza, Connor Sahl, Eve Sprute, Claire Zhu

Please join us in welcoming some of our recent new hires! We're excited to see what we can achieve together as we focus on advancing our innovative solutions. #OcularExperience #NewHires

Join us as we share our Q2 2025 earnings on August 5, where we will highlight key financial outcomes and progress made during the quarter. Learn more: https://ow.ly/GhHW50WwBVj #RetinaRedefined